Martin Rosenberg Ph.D.
Advisor,VantagePoint Capital Partners
|Age||Total Calculated Compensation||This person is connected to 31 board members in 6 different organizations across 7 different industries.|
See Board Relationships
Dr. Martin Rosenberg, Ph.D., also known as Marty, serves as the Chief Scientific Officer at Promega Corporation. Dr. Rosenberg joined Promega in 2001, as the Vice President of Research and Development. Dr. Rosenberg also serves as the Vice President of Research and Development at Nereus Pharmaceuticals Inc. He is also an Advisor in the Healthcare division at VantagePoint Capital Partners. Prior to that, Dr. Rosenberg was a Senior Vice President of Anti-Infectives Drug ...
1001 Bayhill DrivePhone: 650-866-3100
San Bruno, California 94066
Board Members Memberships*
University of Rochester
Yale University School Of Medicine
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
|There is no Competitor Compensation data available.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.